Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2002

View Archived Issues

Dual inhibitor of ECE-1 and NEP demonstrates efficacy in preclinical studies

Partaject-delivered busulfan granted orphan drug status

Quick-Med licenses technologies from U. of Florida

The antisense oligonucleotide oblimersen sodium a highlight of the ASH meeting

Novel agents for ischemic conditions identified by Galileo researchers

GSK presents several series of urotensin-II antagonists

Fujisawa and Daiso present novel compounds with apo B secretion-inhibitory activity

VEGFR inhibitors and their use in psoriasis and other disorders

Bayer presents new thyroid hormone-like compounds for use in arteriosclerosis therapy

Safety restrictions announced for Eprex/Erypo in patients with chronic renal failure

GenVec and Fuso collaborate to develop targeted cancer therapy candidate

Athersys and U. of Minnesota to develop adult stem cell technology

Cell Genesys and VectorLogics collaborate on second-generation oncolytic virus therapies

Corus-1020 completes phase I study

VEGF gene transfer evaluated for diabetic neuropathy in NIH-funded trial

U. of Arkansas to assess CEL-1000 against Chlamydia

Efficacy of bortezomib in hematological malignancies

Tempostatin enters phase II trial for recurring bladder cancer

IDEC-114 reported safe and effective in refractory follicular lymphoma

New data on bryostatin 1 combined with fludarabine in CLL

No objective antitumor responses in AML patients treated with PTK-787/ZK-222584

Disappointing phase III preliminary results for CeaVac in colorectal cancer

AP-158 kills mupirocin-resistant bacteria in vivo

Merck & Co. plans growth in 2003 on two fronts

Oxime tachykinin antagonist with oral activity and potential as an asthma therapy

Merck KGaA announces name changes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...